TY - JOUR
T1 - Mesenchymal Stromal Cells and Their Secretome
T2 - New Therapeutic Perspectives for Skeletal Muscle Regeneration
AU - Sandonà, Martina
AU - Di Pietro, Lorena
AU - Esposito, Federica
AU - Ventura, Alessia
AU - Silini, Antonietta Rosa
AU - Parolini, Ornella
AU - Saccone, Valentina
N1 - Funding Information:
We thank Universit? Cattolica del Sacro Cuore, Rome, and Fondazione Santa Lucia, Rome. We would like to acknowledge the Regenerative Medicine Research Center (CROME) of Universit? Cattolica del Sacro Cuore. This work contributes to the COST Action CA17116 International Network for Translating Research on Perinatal Derivatives into Therapeutic Approaches (SPRINT) and supported by COST (European Cooperation in Science and Technology). Funding. This work has been supported by the following funding: Association Francaise contre les Myopathies (AFM no. 21657) and Italian Ministry of Health (GR-2016-02362451) to VS; Italian Ministry of Research and University, PRIN 2017 (MIUR, grant no. 2017RSAFK7) to OP; 5?1000 year 2018; and Fondazione Poliambulanza.
Publisher Copyright:
© Copyright © 2021 Sandonà, Di Pietro, Esposito, Ventura, Silini, Parolini and Saccone.
PY - 2021/5/13
Y1 - 2021/5/13
N2 - Mesenchymal stromal cells (MSCs) are multipotent cells found in different tissues: bone marrow, peripheral blood, adipose tissues, skeletal muscle, perinatal tissues, and dental pulp. MSCs are able to self-renew and to differentiate into multiple lineages, and they have been extensively used for cell therapy mostly owing to their anti-fibrotic and immunoregulatory properties that have been suggested to be at the basis for their regenerative capability. MSCs exert their effects by releasing a variety of biologically active molecules such as growth factors, chemokines, and cytokines, either as soluble proteins or enclosed in extracellular vesicles (EVs). Analyses of MSC-derived secretome and in particular studies on EVs are attracting great attention from a medical point of view due to their ability to mimic all the therapeutic effects produced by the MSCs (i.e., endogenous tissue repair and regulation of the immune system). MSC-EVs could be advantageous compared with the parental cells because of their specific cargo containing mRNAs, miRNAs, and proteins that can be biologically transferred to recipient cells. MSC-EV storage, transfer, and production are easier; and their administration is also safer than MSC therapy. The skeletal muscle is a very adaptive tissue, but its regenerative potential is altered during acute and chronic conditions. Recent works demonstrate that both MSCs and their secretome are able to help myofiber regeneration enhancing myogenesis and, interestingly, can be manipulated as a novel strategy for therapeutic interventions in muscular diseases like muscular dystrophies or atrophy. In particular, MSC-EVs represent promising candidates for cell free-based muscle regeneration. In this review, we aim to give a complete picture of the therapeutic properties and advantages of MSCs and their products (MSC-derived EVs and secreted factors) relevant for skeletal muscle regeneration in main muscular diseases.
AB - Mesenchymal stromal cells (MSCs) are multipotent cells found in different tissues: bone marrow, peripheral blood, adipose tissues, skeletal muscle, perinatal tissues, and dental pulp. MSCs are able to self-renew and to differentiate into multiple lineages, and they have been extensively used for cell therapy mostly owing to their anti-fibrotic and immunoregulatory properties that have been suggested to be at the basis for their regenerative capability. MSCs exert their effects by releasing a variety of biologically active molecules such as growth factors, chemokines, and cytokines, either as soluble proteins or enclosed in extracellular vesicles (EVs). Analyses of MSC-derived secretome and in particular studies on EVs are attracting great attention from a medical point of view due to their ability to mimic all the therapeutic effects produced by the MSCs (i.e., endogenous tissue repair and regulation of the immune system). MSC-EVs could be advantageous compared with the parental cells because of their specific cargo containing mRNAs, miRNAs, and proteins that can be biologically transferred to recipient cells. MSC-EV storage, transfer, and production are easier; and their administration is also safer than MSC therapy. The skeletal muscle is a very adaptive tissue, but its regenerative potential is altered during acute and chronic conditions. Recent works demonstrate that both MSCs and their secretome are able to help myofiber regeneration enhancing myogenesis and, interestingly, can be manipulated as a novel strategy for therapeutic interventions in muscular diseases like muscular dystrophies or atrophy. In particular, MSC-EVs represent promising candidates for cell free-based muscle regeneration. In this review, we aim to give a complete picture of the therapeutic properties and advantages of MSCs and their products (MSC-derived EVs and secreted factors) relevant for skeletal muscle regeneration in main muscular diseases.
KW - atrophy
KW - extracellular vesicles
KW - mesenchymal stromal cells
KW - muscle
KW - muscle regeneration
KW - muscular dystrophy
KW - secretome
UR - http://www.scopus.com/inward/record.url?scp=85107071814&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85107071814&partnerID=8YFLogxK
U2 - 10.3389/fbioe.2021.652970
DO - 10.3389/fbioe.2021.652970
M3 - Review article
AN - SCOPUS:85107071814
SN - 2296-4185
VL - 9
JO - Frontiers in Bioengineering and Biotechnology
JF - Frontiers in Bioengineering and Biotechnology
M1 - 652970
ER -